<?xml version="1.0" encoding="UTF-8"?>
<p id="Par77">Submission of RMPs and their updates should be considered in the following situations:
 <list list-type="bullet">
  <list-item>
   <p id="Par78">For any new marketing authorisation application.</p>
  </list-item>
  <list-item>
   <p id="Par79">Post-authorisation, when an RMP update or a new RMP needs to be submitted at specific times, for example:
    <list list-type="bullet">
     <list-item>
      <p id="Par80">At the request of the local NRA.</p>
     </list-item>
     <list-item>
      <p id="Par81">With an application involving a change to an existing marketing authorisation when the data included leads to a change in the list of the safety concerns, or when a new additional pharmacovigilance activity or a new risk-minimisation measure is needed or is proposed to be removed.</p>
     </list-item>
    </list>
   </p>
  </list-item>
  <list-item>
   <p id="Par82">Whenever significant new information is available on important risks or missing information in the benefitâ€“risk profile of the medicinal product as well as when there are significant updates to the described pharmacovigilance activities and risk-minimisation measures</p>
  </list-item>
 </list>
</p>
